Your browser is no longer supported. Please, upgrade your browser.
BTAI BioXcel Therapeutics, Inc. monthly Stock Chart
BTAI [NASD]
BioXcel Therapeutics, Inc.
Index- P/E- EPS (ttm)-3.37 Insider Own39.80% Shs Outstand23.05M Perf Week-7.87%
Market Cap1.09B Forward P/E- EPS next Y-4.25 Insider Trans0.00% Shs Float14.67M Perf Month-1.91%
Income-69.40M PEG- EPS next Q-0.96 Inst Own53.90% Short Float20.11% Perf Quarter13.00%
Sales- P/S- EPS this Y-53.00% Inst Trans41.35% Short Ratio6.27 Perf Half Y-5.75%
Book/sh9.59 P/B4.65 EPS next Y-9.00% ROA-64.30% Target Price- Perf Year602.20%
Cash/sh9.57 P/C4.66 EPS next 5Y- ROE-74.20% 52W Range5.58 - 71.50 Perf YTD205.20%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-37.64% Beta-
Dividend %- Quick Ratio14.40 Sales past 5Y- Gross Margin- 52W Low699.10% ATR2.92
Employees40 Current Ratio14.40 Sales Q/Q- Oper. Margin- RSI (14)39.90 Volatility5.45% 6.32%
OptionableYes Debt/Eq0.00 EPS Q/Q-87.60% Profit Margin- Rel Volume0.67 Prev Close44.65
ShortableYes LT Debt/Eq0.00 EarningsNov 12 BMO Payout- Avg Volume470.15K Price44.59
Recom1.60 SMA20-12.19% SMA50-7.80% SMA2005.57% Volume316,627 Change-0.13%
Oct-30-20Initiated Goldman Buy $60
Sep-02-20Initiated Jefferies Buy $82
Aug-17-20Reiterated H.C. Wainwright Buy $200 → $175
Jul-08-20Reiterated H.C. Wainwright Buy $95 → $120
Jun-04-20Initiated Guggenheim Buy $101
Apr-01-20Initiated BofA/Merrill Buy $45
Feb-26-20Reiterated H.C. Wainwright Buy $30 → $95
Jan-08-20Reiterated H.C. Wainwright Buy $25 → $30
Nov-12-19Initiated SunTrust Buy $24
Nov-16-20 09:06AM  
Nov-13-20 07:00AM  
Nov-12-20 07:00AM  
06:45AM  
Nov-11-20 07:00AM  
Nov-09-20 08:05AM  
Nov-05-20 07:00AM  
Oct-26-20 07:00AM  
Sep-25-20 11:25AM  
Sep-09-20 07:00AM  
Aug-21-20 10:20AM  
Aug-17-20 06:02AM  
Aug-14-20 12:34PM  
07:00AM  
Aug-07-20 07:00AM  
Aug-06-20 07:00AM  
Jul-28-20 08:20PM  
Jul-27-20 04:21PM  
Jul-22-20 05:45AM  
Jul-20-20 04:33PM  
04:27PM  
11:44AM  
07:00AM  
Jul-09-20 07:00AM  
Jul-07-20 07:00AM  
Jul-05-20 09:21PM  
Jun-23-20 07:00AM  
Jun-17-20 09:43AM  
Jun-16-20 07:00AM  
Jun-15-20 04:05PM  
Jun-11-20 07:00AM  
Jun-04-20 09:42AM  
May-28-20 07:00AM  
May-15-20 05:45AM  
May-14-20 07:00AM  
May-12-20 10:31PM  
07:00AM  
May-11-20 07:00AM  
May-07-20 07:00AM  
May-05-20 07:00AM  
Apr-28-20 07:00AM  
Apr-24-20 07:21AM  
Mar-24-20 04:23PM  
Mar-19-20 07:15AM  
Mar-17-20 10:55AM  
Mar-09-20 07:00AM  
06:00AM  
Mar-02-20 07:00AM  
Feb-28-20 08:20AM  
Feb-26-20 07:00AM  
Feb-20-20 07:30AM  
Feb-19-20 04:54PM  
07:21AM  
Feb-18-20 07:00AM  
Feb-07-20 07:00AM  
Feb-06-20 07:47AM  
Feb-05-20 07:00AM  
Jan-28-20 06:13PM  
Jan-25-20 09:28AM  
Jan-10-20 06:45AM  
Jan-07-20 07:00AM  
Dec-30-19 07:00AM  
Dec-22-19 07:42PM  
Dec-11-19 07:00AM  
Dec-06-19 06:40AM  
Dec-03-19 07:00AM  
Nov-26-19 07:00AM  
07:00AM  
Nov-21-19 06:30AM  
Nov-14-19 07:00AM  
Nov-07-19 07:00AM  
Oct-30-19 06:00AM  
Oct-27-19 09:51AM  
Oct-24-19 08:00AM  
Oct-10-19 08:00AM  
Sep-26-19 09:11AM  
Sep-25-19 04:27PM  
Sep-18-19 08:00AM  
Sep-04-19 08:00AM  
Aug-20-19 08:00AM  
Aug-06-19 07:30AM  
Jul-31-19 08:00AM  
Jul-30-19 04:01PM  
Jul-29-19 02:34PM  
Jul-26-19 12:21PM  
Jul-22-19 06:00AM  
Jul-01-19 08:00AM  
Jun-18-19 08:00AM  
Jun-10-19 08:00AM  
Jun-06-19 08:00AM  
Jun-03-19 08:00AM  
May-31-19 04:05PM  
May-28-19 11:02AM  
May-20-19 07:30AM  
May-13-19 08:00AM  
May-09-19 08:00AM  
May-07-19 08:00AM  
May-02-19 08:36AM  
Apr-29-19 05:17PM  
11:08AM  
BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent for the treatment of prostate and pancreatic cancers, and other solid tumors. BioXcel Therapeutics, Inc. has a collaboration with Merck KGaA; Nektar Therapeutics, Inc.; and Pfizer Inc. to develop a therapy for treating pancreatic cancer. The company was founded in 2017 and is headquartered in New Haven, Connecticut. BioXcel Therapeutics, Inc. is a subsidiary of BioXcel Corporation.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Yocca FrankChief Scientific OfficerFeb 14Option Exercise0.4180,00032,80088,397Feb 19 05:22 PM